Fiberite 1333A Thermoset Compound

Product Description

Fiberite 1333A was a thermoset molding compound manufactured by Fiberite Corporation, a specialty materials company headquartered in Winona, Minnesota. Fiberite built its commercial reputation on high-performance polymer composites and molding compounds engineered for demanding industrial and electrical applications. The 1333A designation identified a specific phenolic-based formulation within Fiberite’s broader line of thermoset compounds, products designed to be shaped under heat and pressure into finished or semi-finished components that would not soften or re-melt after curing.

Thermoset compounds of this class were valued in industrial settings for their dimensional stability, resistance to elevated temperatures, and electrical insulating properties. Once molded, phenolic thermoset parts could be used in electrical panels, motor housings, circuit breaker components, switchgear, and other applications where mechanical strength and resistance to heat or electrical arc were required. Fiberite supplied molding compounds to original equipment manufacturers and industrial processors across the United States, meaning Fiberite 1333A and related compounds reached a wide range of industrial environments through the products manufactured with them.

Fiberite Corporation operated for decades as a prominent supplier in the composites and specialty plastics industry before being acquired and eventually absorbed into larger materials conglomerates. The company’s products, including its phenolic compound lines, were distributed nationally and used across manufacturing sectors during periods when asbestos-containing formulations were common in industrial materials.

Asbestos Content

Litigation records document that Fiberite 1333A thermoset compound contained asbestos as a functional additive within its phenolic resin matrix. Plaintiffs alleged that asbestos fibers were incorporated into the compound formulation to enhance specific performance characteristics, including heat resistance, dimensional stability under thermal cycling, and mechanical strength after molding.

Asbestos was a well-established filler and reinforcing agent in phenolic molding compounds during much of the twentieth century. Its fibrous structure allowed it to distribute mechanical stresses within the cured resin, and its thermal properties complemented the inherent heat resistance of phenolic chemistry. Litigation records document that compounds such as Fiberite 1333A were among the asbestos-containing thermoset formulations used in industrial and electrical manufacturing contexts.

The specific asbestos fiber type or types present in Fiberite 1333A have been addressed through litigation discovery and related proceedings. Chrysotile, amosite, and other asbestos varieties were used in different phenolic compound formulations during the relevant production periods, depending on the intended application and the supplier relationships maintained by the manufacturer. Plaintiffs alleged that Fiberite failed to provide adequate warnings about the asbestos content of its molding compounds and the hazards associated with occupational exposure during normal processing and fabrication activities.

How Workers Were Exposed

Industrial workers who handled, processed, or worked in proximity to operations using Fiberite 1333A thermoset compound faced potential asbestos exposure through several recognized pathways. Thermoset molding compounds in this category were not inert finished products—they required active processing steps that could disturb and release asbestos fibers into the workplace atmosphere.

Receiving and material handling presented early exposure opportunities. Workers who unloaded, stored, or transferred bulk molding compound encountered the material in a form that could generate airborne dust, particularly if packaging was damaged or material was transferred by scooping, pouring, or conveying.

Compression and transfer molding operations were a primary exposure pathway. Loading measured quantities of compound into molds, operating molding presses, and removing finished parts all involved direct contact with the compound in various states. The heat and pressure of the molding cycle could also volatilize and release material at mold edges and parting lines, creating localized airborne contamination.

Deflashing and finishing operations carried significant exposure potential. After molding, thermoset parts characteristically retain flash—thin ridges of excess material at mold parting lines—that required removal by mechanical trimming, grinding, or tumbling. These operations generated fine airborne dust that could contain asbestos fibers released from the cured resin matrix. Plaintiffs alleged that finishing and deflashing work exposed workers to elevated concentrations of asbestos-containing particulate.

Machining and secondary fabrication added further risk. Drilling, sawing, routing, or sanding cured phenolic parts could release encapsulated asbestos fibers, creating respirable dust in machining areas. Workers performing these tasks without adequate engineering controls or respiratory protection could inhale asbestos fibers over the course of normal workdays.

Maintenance and janitorial personnel in facilities where Fiberite 1333A was processed were also potentially exposed through accumulated dust on surfaces, equipment, and in ventilation systems. Litigation records document that bystander and ambient exposure in industrial molding environments was a recognized concern in cases involving asbestos-containing thermoset compounds.

The diseases associated with occupational asbestos exposure—including mesothelioma, asbestosis, and asbestos-related lung cancer—typically have latency periods of ten to fifty years between initial exposure and diagnosis. This means workers exposed to Fiberite 1333A during its production and distribution years may only now be receiving diagnoses related to that exposure.

Documented Trust Fund / Legal Options

Fiberite 1333A is classified as a Tier 2 litigated product. No dedicated Fiberite Corporation asbestos bankruptcy trust fund has been identified in publicly available trust fund documentation maintained under AHERA or related federal frameworks. Legal claims arising from exposure to Fiberite 1333A and related thermoset compounds have proceeded through the civil litigation system rather than through an administrative trust fund claims process.

Litigation records document that plaintiffs diagnosed with mesothelioma, lung cancer, asbestosis, and other asbestos-related diseases have brought claims alleging that Fiberite Corporation manufactured and distributed asbestos-containing molding compounds without adequate hazard warnings, and that this failure to warn contributed to occupational asbestos exposure and resulting disease.

Individuals who may have legal options include:

• Industrial workers who handled, molded, finished, or machined Fiberite 1333A or similar phenolic thermoset compounds
• Workers employed at facilities where Fiberite molding compounds were processed, including those in adjacent trades or maintenance roles
• Individuals diagnosed with mesothelioma, asbestos-related lung cancer, asbestosis, or pleural disease with a work history that included exposure to industrial molding compounds

Practical considerations for potential claimants:

Because Fiberite 1333A claims proceed through civil litigation rather than a trust fund, the claims process involves different timelines, evidentiary requirements, and legal procedures than trust fund submissions. Statutes of limitations for asbestos-related disease claims vary by state and typically run from the date of diagnosis or discovery of disease, not from the date of exposure.

Individuals or surviving family members seeking to evaluate potential claims should consult with an attorney experienced in asbestos litigation. Documentation of work history, employer records, product identification, and medical records supporting an asbestos-related diagnosis are all relevant to the claims evaluation process.

This article is provided for informational reference purposes. It does not constitute legal advice, and individuals with potential claims should seek qualified legal counsel.